BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35326415)

  • 1. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.
    Weimer P; Wellbrock J; Sturmheit T; Oliveira-Ferrer L; Ding Y; Menzel S; Witt M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Brauneck F
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
    Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
    Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
    [No Abstract]   [Full Text] [Related]  

  • 3. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
    Marius W; Leticia OF; Friedrich KN; Stephan M; Louisa H; Tabea S; Elisa S; Pauline W; Yi D; Qi M; Barbara S; Carsten B; Walter F; Jasmin W; Franziska B
    Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.
    Tassi E; Bergamini A; Wignall J; Sant'Angelo M; Brunetto E; Balestrieri C; Redegalli M; Potenza A; Abbati D; Manfredi F; Cangi MG; Magliacane G; Scalisi F; Ruggiero E; Maffia MC; Trippitelli F; Rabaiotti E; Cioffi R; Bocciolone L; Candotti G; Candiani M; Taccagni G; Schultes B; Doglioni C; Mangili G; Bonini C
    Front Immunol; 2023; 14():1212444. PubMed ID: 37868997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
    Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression.
    Kolbe K; Wittner M; Hartjen P; Hüfner AD; Degen O; Ackermann C; Cords L; Stellbrink HJ; Haag F; Schulze Zur Wiesch J
    Front Immunol; 2022; 13():867167. PubMed ID: 35529864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
    Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
    Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrahepatic CD69
    Bruni E; Cimino MM; Donadon M; Carriero R; Terzoli S; Piazza R; Ravens S; Prinz I; Cazzetta V; Marzano P; Kunderfranco P; Peano C; Soldani C; Franceschini B; Colombo FS; Garlanda C; Mantovani A; Torzilli G; Mikulak J; Mavilio D
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
    Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
    [No Abstract]   [Full Text] [Related]  

  • 14. Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs.
    Eiva MA; Omran DK; Chacon JA; Powell DJ
    Eur J Immunol; 2022 Jan; 52(1):96-108. PubMed ID: 34505280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vδ1 Effector and Vδ2 γδ T-Cell Subsets Shift in Frequency and Are Linked to Plasma Inflammatory Markers During Antiretroviral Therapy-Suppressed HIV Infection.
    Pihl RMF; Smith-Mahoney EL; Olson A; Yuen RR; Asundi A; Lin N; Belkina AC; Snyder-Cappione JE
    J Infect Dis; 2024 May; 229(5):1317-1327. PubMed ID: 38390982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of the expression of γδ T cells and their co-stimulatory molecules TIGIT, PD-1, ICOS and BTLA with PR and PIBF in the peripheral blood and decidual tissues of women with unexplained recurrent spontaneous abortion.
    Liang Q; Tong L; Xiang L; Shen S; Pan C; Liu C; Zhang H
    Clin Exp Immunol; 2021 Jan; 203(1):55-65. PubMed ID: 33017473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
    Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
    Front Immunol; 2020; 11():340. PubMed ID: 32174925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
    Fleury M; Belkina AC; Proctor EA; Zammitti C; Simms RW; Lauffenburger DA; Snyder-Cappione JE; Lafyatis R; Dooms H
    Arthritis Rheumatol; 2018 Apr; 70(4):566-577. PubMed ID: 29245183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
    Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
    Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.